ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AVO Advanced Oncotherapy Plc

1.925
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Advanced Oncotherapy Plc LSE:AVO London Ordinary Share GB00BD6SX109 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.925 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Medical Laboratories 0 -29.49M -0.0549 -0.35 10.32M

Advanced Oncotherapy PLC Total Voting Rights (3530Q)

26/02/2021 5:00pm

UK Regulatory


Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Advanced Oncotherapy Charts.

TIDMAVO

RNS Number : 3530Q

Advanced Oncotherapy PLC

26 February 2021

26 February 2021

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or the "Company")

Total Voting Rights

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that the Company's issued share capital as at the date of this announcement comprises 349,040,614 ordinary shares of 25p each, with one voting right per share ("Ordinary Shares"). The Company does not hold any ordinary shares in treasury and therefore the total number of Ordinary Shares with voting rights in the Company is 349,040,614.

The above figure of 349,040,614 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

 
 Advanced Oncotherapy plc                                                        www.avoplc.com 
 Dr Michael Sinclair, Executive Chairman                              Tel: +44 (0) 20 3617 8728 
 Nicolas Serandour, CEO 
 
 Allenby Capital Limited (Nomad and Joint Broker) 
 Nick Athanas / Liz Kirchner (Corporate Finance)                      Tel: +44 (0) 20 3328 5656 
  Amrit Nahal / Matt Butlin (Sales & Corporate Broking) 
 
 SI Capital Ltd (Joint Broker) 
 Nick Emerson                                                         Tel: +44 (0) 1483 413 500 
 Jon Levinson                                                         Tel: +44 (0) 20 3871 4066 
 
 FTI Consulting (Financial PR & IR)                       advancedoncotherapy@fticonsulting.com 
 Simon Conway / Rob Winder                                            Tel: +44 (0) 20 3727 1000 
 

Notes for Editors

About Advanced Oncotherapy Plc www.avoplc.com

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVREAEASAANFEFA

(END) Dow Jones Newswires

February 26, 2021 12:00 ET (17:00 GMT)

1 Year Advanced Oncotherapy Chart

1 Year Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart

1 Month Advanced Oncotherapy Chart

Your Recent History

Delayed Upgrade Clock